Dolutegravir + emtricitabine + tenofovir disoproxil fumarate

Dolutegravir + emtricitabine + tenofovir disoproxil fumarate has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Oct 20, 2026: “Immune gene variants linked to virus control in aged macaques”.

Intervention

1 paper studies it1 findingUpdated

PubChemPubChemPubChemChEBIChEBIChEBI

  • 1 lab in 1 country
  • Funder: National Institute of Allergy and Infectious Diseases
  • Animals1

What did studies of Dolutegravir + emtricitabine + tenofovir disoproxil fumarate find?

1

Studies of Dolutegravir + emtricitabine + tenofovir disoproxil fumarate measured 1 outcome; the most studied are plasma viral load (1 study).

Plasma viral load

downin rhesus monkeys1

1 study
  1. Dolutegravir + emtricitabine + tenofovir disoproxil fumarate decreases plasma viral load in rhesus monkeys.

    “While antiretroviral therapy substantially reduced PVL in both groups”

    AnimalsSIVmac239 infection; both MHC+ and MHC- groupsplasma15 weeks

    Immune gene variants linked to virus control in aged macaques

    Journal of immunology (Baltimore, Md. : 1950)

More on Plasma viral load

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 11 paper in 12 months
Journal of Immunology

Immune gene variants linked to virus control in aged macaques

In an infection experiment, rhesus macaques aged 17–23 with protective immune gene variants had lower blood virus levels through 70 days than those without.In an infection experiment, rhesus macaques aged 17–23 with protective immune gene variants had lower blood virus levels through 70 days than those without.

Animal study · 16 animalsBlood and immune system